The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Very dangerous time to play this share now. We are moving into a pivotal moment for ODX.
or low?
"Ready for the explosion on Tuesday." Go easy on those sprouts!
COVID-19: Less than half of UK population could be vaccinated in 2021, spending watchdog says. https://www.google.com/amp/s/news.sky.com/story/amp/covid-19-less-than-half-of-uk-population-could-be-vaccinated-in-2021-spending-watchdog-says-12162805
Are you serious? These are brand new vaccines. Nobody has a clue how long immunity will last! Antibody testing will be bigger than ever.
Nicholas A. Christakis is the Sterling Professor of Social and Natural Science at Yale University, where he also directs the Human Nature Lab, and serves as Co-Director of the Yale Institute for Network Science. Play from here for his take on immunity and the vaccine. We'll be testing for a LONG time. https://youtu.be/Sc5oa6MqPDg?t=2920
Behind the Covid-19 vaccine is a hidden arsenal of diagnostic tests: https://www.telegraph.co.uk/global-health/science-and-disease/behind-covid-19-vaccines-hidden-arsenal-diagnostic-tests/
As ever, spot on with that analysis, Merchantbanker. Worth a repost:
"Share price will probably burst into life when least expected. Said this when it was stuck in the 50p range and not reacting to news because of a seller.
Since the first time that it hit 80p, we have seen the following progress:
Firm RNS/Presentation confirmation:
Ulster Uni report confirming performance sensitivity and specificity to be excellent First UK Gov contract
UK RTC supply agreement with price per test slightly ahead of expectations, and at least 25% of total supply
Clear evidence of Visitect triple antibody sales via distribution presence and confirmation of early traction by CK and that Nov production is already consumed
Clear plans to increase production up beyond the 1m LFT from the investment prospectus to 2-2.5m, and confirmation that funding is in place to do so and declaration by CK that it is in relation to operation Moonshot
China Food Test Self Test approval
Also circumstantial evidence as follows:
Suggestion that Mologic test is a matter of days away from approval
Antigen test described as xmas present with Tech transfer due to commence within the next 4 weeks.
Mologic LFT antigen test has been used in various health settings trials including Heathrow and Nottingham drive throughs.
Boris confirming that the UK is gearing up towards being ready for lateral flow tests hit the market
Further evidence suggesting Covid 19 is a much longer term problem and therefore commercial opportunity than many first thought, with years of testing required
UK RTC being the only antibody test going for MHRA self test approval with still talks of mass testing and using the same reagents and the Oxford vaccine programme with a clear link to vaccine immunity efficacy
What you have to look at is does it make sense for the lack of share price reaction. You would struggle to find a case to say it does make sense. With evidence of large sellers at any price, it is clear this is not achieving the value it deserves. When you add in the wider market decline with the lockdown, which really should make a stronger case for ODX, I can only see this as a bargain share price. All this talk about the company not doing a good job with PR is nonsense, because the items they are delivering highly cash generative and will translate into healthy profits. But when you are up against 20-30% of the company being sold off at any price due to them already being significantly in profit and selling based on factors that are not driven by the investment peaking it's potential, then there will be a lag in the share price achieving the growth it deserves. It will get there and it offers great opportunity to those that can take advantage.
"0.5m lateral flow tests a week[!!] to match expected demand".
By end of 2020 we will have production capacity at our Alva site for 0.5m lateral flow tests a week to match expected demand:
White heavy check mark 200k tests a week min for AbC-19 Rapid Tests
White heavy check mark some CD4 test production
White heavy check mark the rest for Mologic antibody and antigen test production
LOL, if you look at the guy who wrote the article, Ethan Ennals, his background is in "creating social media content" for a theatre, and looking after artists at the Edinburgh Fringe Festival. No medical background whatsoever. Anything for click bait.
And the rest!
VISITECT Rapid Finger Prick Antibody Test
£475.00
Screen4 Ltd have teamed up with one of the largest diagnostic businesses across the globe – Omega Diagnostics. Enabling us to offer Practitioners, Clinics, Pharmacies, Occupational Health businesses and teams access to the latest VISITECT® Covid19 Rapid Finger prick Antibody Test.
*The only rapid test that identifies all 3 antibodies (IgM, IgA and IgG), increasing the window of detection.*
This Qualitative rapid diagnostic test detects IgM, IgA and IgG antibodies. The manual lateral flow immunoassay is for proffessional use only and is not to be used for self-testing.
The kits come with 25 test devices plus buffer, swabs, lancets and blood transfer cups. The devices are all CE marked.
Each test costs £19.00 each and they can only be purchased in boxes of 25.
News flow is now imminent, but the “significant orders and interest from African, Latin American and Asian countries” is what really caught my attention. The hard work will soon pay off.
Should they be successful with trials, etc., what parts will they be supplying? Surely, it will make a huge difference if it's electrical components and hardware that will last months/years with a relatively limited number of machines, as opposed to test strips etc, which would be high turn-over...?
Says the poster who spends all his/her time on here obsessing over ODX. LOL
"If coronavirus is like flu and people need an annual vaccine, we will need mass antibody testing to measure people's antibody response to that vaccine. That's part of the plan," Dr Hand said.
"At the moment, this test is a tool to gather knowledge," Dr Hand said. "The objective is to allow mass testing, which you can't really do by sending samples to a lab. By being able to test millions of people, it will gather information so that we know how many people have antibodies, whether they protect against reinfection and how long they last."
"We're using a particular capture mechanism for the antibodies which allows our test to be very sensitive," Dr Hand said.
"As far as we know, others were using other smaller fractions of the virus. Our scientific opinion and that of Oxford University is that the full-length spike protein is the way to go."
"This rapid test appears to be truly amazing, and it shows we can do this ourselves," said Sir John Bell, Oxford's Regius Professor of Medicine, who leads the Government's antibody testing programme.
"If coronavirus is like flu and people need an annual vaccine, we will need mass antibody testing to measure people's antibody response to that vaccine. That's part of the plan," Dr Hand said.
"At the moment, this test is a tool to gather knowledge," Dr Hand said. "The objective is to allow mass testing, which you can't really do by sending samples to a lab. By being able to test millions of people, it will gather information so that we know how many people have antibodies, whether they protect against reinfection and how long they last."
The many reasons why we invest in ODX:
"We're using a particular capture mechanism for the antibodies which allows our test to be very sensitive," Dr Hand said.
"As far as we know, others were using other smaller fractions of the virus. Our scientific opinion and that of Oxford University is that the full-length spike protein is the way to go."
"This rapid test appears to be truly amazing, and it shows we can do this ourselves," said Sir John Bell, Oxford's Regius Professor of Medicine, who leads the Government's antibody testing programme.